8-K: Cardiff Oncology: Leadership Shift & Positive Cancer Trial Data

Cardiff Oncology announced a leadership transition with a new interim CEO and positive Phase 2 clinical trial results for onvansertib in RAS-mutated metastatic colorectal cancer.

Summary

• Cardiff Oncology announced a leadership transition, with Dr. Mark Erlander (CEO) and James Levine (CFO) stepping down on January 27, 2026.
• Dr. Mani Mohindru, a member of the Board of Directors, has been appointed interim CEO, effective January 27, 2026.
• Brigitte Lindsay, Senior Vice President of Finance, has been promoted to Chief Accounting Officer, effective January 27, 2026.
• The company reported positive results from CRDF-004, a randomized Phase 2 clinical trial evaluating onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC).
• Onvansertib, when combined with FOLFIRI/bevacizumab (bev), demonstrated dose-dependent benefits across multiple efficacy measures.
• The 30 mg dose of onvansertib with FOLFIRI/bev has been selected for a registrational program in first-line RAS-mutated mCRC.
• The 30 mg onvansertib + FOLFIRI/bev arm achieved an Objective Response Rate (ORR) of 72.2% (n=18) compared to 43.2% (n=37) for the standard of care (SoC) arms (p-value = 0.051).
• The 30 mg onvansertib + FOLFIRI/bev arm showed a statistically significant improvement in Progression-Free Survival (PFS) compared to SoC (Hazard Ratio 0.37, p-value = 0.048).
• Onvansertib in combination with both chemo/bev regimens was safe and well-tolerated, with no major or unexpected toxicities and no additive adverse events.
• The company expects to provide final data and registrational plans in the first half of 2026 and plans to initiate a registrational program later this year, pending FDA consultation.

Sentiment

Score: 8

Explanation: The positive Phase 2 clinical trial results for onvansertib in a high unmet need area, showing statistically significant improvements in PFS and a substantially higher ORR compared to standard of care, are very encouraging. The appointment of an experienced interim CEO is a positive step for strategic direction. However, the departure of both the CEO and CFO introduces some uncertainty, and the company will need to successfully navigate the search for permanent leadership and the subsequent registrational trial.

Positives

• Positive Phase 2 clinical trial results for onvansertib in first-line RAS-mutated mCRC, demonstrating dose-dependent benefits.
• Onvansertib 30 mg + FOLFIRI/bevacizumab achieved a 72.2% Objective Response Rate (ORR), significantly higher than the 43.2% ORR for standard of care (SoC).
• Statistically significant improvement in Progression-Free Survival (PFS) for onvansertib 30 mg + FOLFIRI/bevacizumab compared to SoC (p-value = 0.048).
• The drug was safe and well-tolerated with no major or unexpected toxicities, and no additive adverse events were observed.
• The results validate previously reported positive findings from a Phase 2 trial of onvansertib in second-line mCRC.
• Dr. Mani Mohindru, an experienced biotechnology executive with a strong background in drug development, corporate strategy, and capital markets, has been appointed interim CEO.
• Brigitte Lindsay's promotion to Chief Accounting Officer ensures continuity and stability within the finance function.

Negatives

• The simultaneous departure of both the Chief Executive Officer and Chief Financial Officer introduces a period of executive transition and potential uncertainty.
• The company has initiated a search for permanent executive leadership, which may take time and resources.
• The p-value for ORR (0.051) for the 30 mg onvansertib arm versus SoC is just above the conventional statistical significance threshold of 0.05, although still highly encouraging.
• The clinical trial results are based on relatively small patient numbers (n=18 per onvansertib arm), which will require confirmation in larger registrational trials.

Risks

• Clinical trials are lengthy, expensive, and have uncertain outcomes, and results from earlier studies may not be predictive of future trial results.
• Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude product approval.
• Results of preclinical studies or clinical trials for the product candidate could be unfavorable or delayed.
• The company may require additional financing to fund its operations and clinical development programs.
• Risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on information technology infrastructure.
• Uncertainties regarding government or third-party payer reimbursement for the product candidate.
• Dependence on key personnel, including the ability to successfully recruit and retain a permanent CEO and CFO.
• Limited experience in marketing and sales, which could impact future commercialization efforts.
• Substantial competition in the oncology sector from other pharmaceutical and biotechnology companies.
• Uncertainties of patent protection and potential litigation related to intellectual property.
• Dependence upon third parties for various aspects of drug development, manufacturing, and commercialization.
• Risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.
• No guarantees that the product candidate will be utilized or prove to be commercially successful.
• No guarantees that future clinical trials will be completed or successful, or that the product candidate will receive regulatory approval for any indication.

Future Outlook

The company plans to rapidly move forward with the onvansertib 30 mg dose in combination with FOLFIRI/bevacizumab for a registrational program in first-line RAS-mutated mCRC. They expect to finalize the trial design in consultation with the FDA and initiate the program later this year. Confirmatory data from a registrational trial has the potential to establish this regimen as a new standard of care for this patient population. Final data and registrational plans are anticipated in the first half of 2026. The company is also searching for permanent executive leadership.

Management Comments

• "We observed a consistent, dose-dependent treatment benefit across multiple measures of efficacy, including achieving statistical significance for PFS compared to SoC even with relatively small patient numbers." Dr. Mani Mohindru, interim CEO.
• "The 30 mg onvansertib-FOLFIRI/bev arm outperformed both SoC arms with no significant additive toxicity, supporting findings from our previous Phase 2 trial in second-line RAS-mutated mCRC." Dr. Mani Mohindru, interim CEO.
• "Our plan is to rapidly move forward with the onvansertib 30 mg dose in combination with FOLFIRI/bev and we believe confirmatory data from a registrational trial has the potential to make this regimen a new SoC for 1L treatment of RAS-mutated mCRC." Dr. Mani Mohindru, interim CEO.
• "We want to express our sincere gratitude to Mark and Jamie for their significant contributions in guiding Cardiff to where it stands today—especially in the progress of our lead product candidate in first-line RAS-mutated mCRC, an area of high unmet need where there have not been any significant advancements in many years." Rodney S. Markin, MD, PhD, Chairman of the Board.
• "Looking forward, we are confident in Dr. Mohindru’s ability to lead the Company at this key moment in onvansertib’s clinical development, as she brings a rare combination of deep scientific training, operational leadership, and capital markets expertise." Rodney S. Markin, MD, PhD, Chairman of the Board.

Industry Context

The announcement addresses a significant unmet need in first-line RAS-mutated metastatic colorectal cancer (mCRC), a patient population that has not seen substantial treatment advancements in over two decades. The development of a novel PLK1 inhibitor like onvansertib, showing promising efficacy and safety, could represent a meaningful breakthrough in a challenging-to-treat cancer. The focus on RAS-mutated mCRC positions Cardiff Oncology in a specific niche within the broader oncology market, where targeted therapies are increasingly sought after. The positive results, if confirmed in larger trials, could shift the standard of care for this patient group.

Comparison to Industry Standards

• First-line treatment for RAS-mutated mCRC has not significantly improved for more than two decades, indicating a high unmet need and a low bar for significant advancement.
• The observed Objective Response Rate (ORR) of 72.2% for onvansertib 30 mg + FOLFIRI/bev significantly outperforms the 43.2% ORR for the current standard of care (SoC) regimens (FOLFIRI/bev or FOLFOX/bev). This represents a substantial improvement over existing therapies.
• The statistically significant improvement in Progression-Free Survival (PFS) (p-value = 0.048) for the 30 mg onvansertib combination compared to SoC, even with relatively small patient numbers, suggests a clinically meaningful benefit.
• The safety profile, with no major or unexpected toxicities and no additive adverse events, is comparable to or better than existing regimens, which is crucial for combination therapies.
• The results validate previous positive findings from a Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC, suggesting consistency in the drug's efficacy profile across different treatment lines.
• Dr. J Randolph Hecht, MD, Professor of Clinical Medicine at UCLA, noted that these preliminary responses and PFS results are "encouraging enough to test in a large Phase 3 trial" and "If such a trial were positive, it could become a new standard of care for these patients," highlighting the potential for onvansertib to set a new benchmark.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to strong clinical trial results for a lead product candidate, which could increase the company's valuation and future revenue potential. However, executive leadership changes introduce short-term uncertainty.
• Patients (RAS-mutated mCRC): Significant positive impact as onvansertib shows potential to become a new, more effective first-line treatment option for a patient population with high unmet medical need.
• Employees: Changes in top leadership may create uncertainty but also opportunities for growth and new strategic direction under the interim CEO.
• Regulatory Authorities (FDA): The positive Phase 2 data will be crucial for discussions with the FDA regarding the design and initiation of a registrational trial.
• Competitors: The positive data for onvansertib could intensify competition in the mCRC treatment landscape, particularly for RAS-mutated forms.

Next Steps

• Initiate a search for a permanent Chief Executive Officer and Chief Financial Officer.
• Finalize the design of the registrational program for onvansertib in first-line RAS-mutated mCRC in consultation with the FDA.
• Initiate the registrational program later this year (2026).
• Provide final data and registrational plans in the first half of 2026.
• Continue evaluating onvansertib in other PLK1-driven cancers through investigator-initiated studies (mPDAC, SCLC, TNBC, CMML).

Key Dates

Recommendation

The clinical trial results for onvansertib in first-line RAS-mutated mCRC are exceptionally strong, demonstrating a statistically significant improvement in Progression-Free Survival and a substantially higher Objective Response Rate compared to the current standard of care. This addresses a critical unmet medical need in a large patient population that has seen little advancement in decades. The safety profile is also favorable. While the executive leadership transition introduces some short-term uncertainty, the appointment of an experienced interim CEO and the clear path to a registrational trial for a potentially practice-changing drug outweigh these concerns. The potential for onvansertib to become a new standard of care positions Cardiff Oncology for significant future growth and market penetration.

Keywords

Cardiff Oncology, CRDF, onvansertib, PLK1 inhibitor, RAS-mutated colorectal cancer, mCRC, metastatic colorectal cancer, oncology, clinical trial, Phase 2, FOLFIRI/bevacizumab, cancer therapy, biotechnology, drug development, CEO change, CFO change, corporate governance, clinical data, objective response rate, progression-free survival, FDA, registrational program